) presented positive data on Adcetris at the 2014 Bone Marrow
Transplant (BMT) Tandem Meeting. Shares rose 2.4% on the
Adcetris is approved for the treatment of relapsed or
refractory Hodgkin lymphoma (HL) and systemic anaplastic large
cell lymphoma (sALCL). Seattle Genetics is looking to expand
Adcetris' label. Interim data was presented from a phase I/II
study to evaluate Adcetris in combination with Treanda for HL
patients after first relapse.
The single-arm, open-label study is divided into two cohorts.
The cohorts' primary endpoint is to find the recommended dosing
level of Treanda in combination with Adcetris and evaluate the
safety and tolerability of this combination.
The study revealed that after a median of two cycles of
therapy, 92% of patients who were evaluated for response achieved
an objective response. Data showed that 77% achieved complete
remission while 15% showed partial remission.
Seattle Genetics also completed the treatment of all patients
in a phase III study, AETHERA. The study is evaluating HL
patients following autologous stem cell transplant. Patient
demographics from this study were also presented at the
The primary endpoint of the randomized, double-blind,
placebo-controlled study is progression-free survival. In
response to salvage therapy, 38% of patients achieved complete
remission while 34% showed partial remission. In response
relating to frontline therapy, 60% of patients were refractory
and 33% relapsed in less than 12 months. The primary efficacy
results will be out in the second half of 2014.
Seattle Genetics carries a Zacks Rank #3 (Hold). Adcetris is
at present approved in 39 countries. Adcetris' revenues in the
year 2013 were $144.7 million. We expect investor focus to remain
on the sales ramp up of the drug and further label expansion.
Investors looking for better-ranked stocks in the pharma
sector may consider companies like
Forest Laboratories Inc.
Lannett Co., Inc.
). Actavis carries a Zacks Rank #2 (Buy) while Lannett and Forest
Labs carry a Zacks Rank #1 (Strong Buy).
ACTAVIS PLC (ACT): Free Stock Analysis Report
FOREST LABS A (FRX): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
SEATTLE GENETIC (SGEN): Free Stock Analysis
To read this article on Zacks.com click here.